VistaGen Therapeutics Price To Sales vs. Target Price

VTGN Stock  USD 2.60  0.13  4.76%   
Based on VistaGen Therapeutics' profitability indicators, VistaGen Therapeutics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess VistaGen Therapeutics' ability to earn profits and add value for shareholders.

VistaGen Therapeutics Price To Sales Ratio

56.54

At this time, VistaGen Therapeutics' Days Sales Outstanding is very stable compared to the past year. As of the 26th of November 2024, Days Of Sales Outstanding is likely to grow to 23.36, while Price To Sales Ratio is likely to drop 56.54. At this time, VistaGen Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 26th of November 2024, Net Interest Income is likely to grow to about 3.5 M, though Operating Income is likely to grow to (31.4 M).
For VistaGen Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of VistaGen Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well VistaGen Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between VistaGen Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of VistaGen Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Revenue Per Share
0.029
Quarterly Revenue Growth
(0.34)
Return On Assets
(0.39)
Return On Equity
(0.62)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

VistaGen Therapeutics Target Price vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining VistaGen Therapeutics's current stock value. Our valuation model uses many indicators to compare VistaGen Therapeutics value to that of its competitors to determine the firm's financial worth.
VistaGen Therapeutics is rated second in price to sales category among its peers. It is currently under evaluation in target price category among its peers . At this time, VistaGen Therapeutics' Price To Sales Ratio is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VistaGen Therapeutics' earnings, one of the primary drivers of an investment's value.

VistaGen Target Price vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

VistaGen Therapeutics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
86.58 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

VistaGen Therapeutics

 = 
13.0

VistaGen Target Price Comparison

VistaGen Therapeutics is currently under evaluation in target price category among its peers.

VistaGen Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in VistaGen Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, VistaGen Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of VistaGen Therapeutics' change in net profit over the period of time. It can combine multiple indicators of VistaGen Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-33 M-31.4 M
Income Before Tax-29.4 M-30.8 M
Net Loss-29.4 M-30.8 M
Income Tax ExpenseK2.5 K
Total Other Income Expense Net3.7 M3.8 M
Net Loss-29.4 M-30.8 M
Non Operating Income Net Other-26.1 K-27.4 K
Net Loss-53.3 M-50.7 M
Net Interest Income3.4 M3.5 M
Interest Income30.1 K19.3 K
Change To Netincome3.1 MM
Net Loss(1.52)(0.46)
Income Quality 0.88  0.77 
Net Income Per E B T 1.00  1.00 

VistaGen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on VistaGen Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of VistaGen Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the VistaGen Therapeutics' important profitability drivers and their relationship over time.

Use VistaGen Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

VistaGen Therapeutics Pair Trading

VistaGen Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your VistaGen Therapeutics position

In addition to having VistaGen Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Municipals ETFs Thematic Idea Now

Municipals ETFs
Municipals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Municipals ETFs theme has 109 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Municipals ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out World Market Map.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
To fully project VistaGen Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of VistaGen Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include VistaGen Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential VistaGen Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although VistaGen Therapeutics investors may work on each financial statement separately, they are all related. The changes in VistaGen Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VistaGen Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.